The American Society for Radiation Oncology (ASTRO) has been awarded a new one-year contract from the U.S. Department of Veterans Affairs (VA) to develop quality indicators (QI) for radiation treatments provided to veterans with head and neck, breast and gastrointestinal cancers

February 13, 2020 — The American Society for Radiation Oncology (ASTRO) has been awarded a new one-year contract from the U.S. Department of Veterans Affairs (VA) to develop quality indicators (QI) for radiation treatments provided to veterans with head and neck, breast and gastrointestinal cancers.
“This pioneering effort leverages evidence-based guidelines and the consensus of medical experts in a new and powerful way to optimize care for military veterans,” said Theodore L. DeWeese, M.D., FASTRO, Chair of the ASTRO Board of Directors. “VA’s leadership in this area is impressive. ASTRO is honored to work with VA in this effort to promote high quality care to our nation’s veterans.”
More than 16,000 veterans receive radiation oncology care through 40 VA clinics nationwide each year. The new metrics will support the VA Radiation Oncology Quality Surveillance program (VA-ROQS), which was established to standardize and improve services at these facilities. Recently, ASTRO partnered with VA to establish QI for lung and prostate cancers forming the evidence basis for the VA-ROQS program.
The goal of VA-ROQS is to combine information technology with clinical expertise to provide physicians with real-time, evidence-based feedback on areas of quality-related performance. Data gathered from these QI, such as radiation dosing or treatment delivery, can then be used by VA-ROQS for quality assessments that show how an individual case scores against national benchmarks and other VA practitioners. The VA-ROQS program allows VA physicians to pinpoint areas for improvement and make meaningful adjustments in their patient care.
ASTRO previously worked with VA and Washington University on the national Radiation Oncology Practice Assessment (ROPA) program. ROPA, the pilot study for VA-ROQS, created the methodology and IT infrastructure while providing comprehensive QI for VA radiation oncologists treating patients with prostate or lung cancers. From 2016 to 2018, the program evaluated more than 1,500 patient cases across the 40 VA facilities, and a recent analysis indicates that from the outset more than 80% of these cases met or exceeded quality standards.
For more information: www.astro.org

Related Content

News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | Molecular Imaging

Sept. 22, 2026 — Blue Earth Diagnostics, a part of the Bracco Group, has announced new research examining how precision ...

Time September 23, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
News | Radiation Therapy

Aug. 13, 2026 — An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence ...

Time August 17, 2026
arrow
News | Prostate Cancer

Aug. 13, 2026 — Artera has announced the enrollment of the first patient in its DIRECT-AI registry study, marking the ...

Time August 14, 2026
arrow
Subscribe Now